Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
Pacific Biosciences Still Can't Catch A Break
02:34pm, Tuesday, 07'th Apr 2020
An adverse ruling in patent litigation against Oxford Nanopore continues a string of negative developments for this life sciences company. Fourth quarter Sequel
Jane Street Group LLC Has $357,000 Holdings in Pacific Biosciences of California (NASDAQ:PACB)
10:02am, Tuesday, 07'th Apr 2020
Jane Street Group LLC raised its position in Pacific Biosciences of California (NASDAQ:PACB) by 78.5% during the fourth quarter, according to the company in its most recent disclosure with the Securit
Worldwide RNA Sequencing Market to 2028 - Hybridization of Technologies Presents Opportunities - ResearchAndMarkets.com
03:53pm, Monday, 06'th Apr 2020
The "Global RNA Sequencing Market: Focus on Product, Technology, Workflow, End User, Application, Region, and Competitive Landscape - Analysis and Forecast, 2019-2028" report has been added to Researc
Dublin, April 06, 2020 -- The "Gene Expression Analysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to.
Should You Buy Illumina Stock During the Coronavirus Bear Market?
11:40am, Sunday, 05'th Apr 2020
This gene-sequencing pioneer hasn't been immune to the coronavirus' effects. But do Illumina's long-term prospects outweigh any short-term pain?
Pacific Biosciences of California (NASDAQ:PACB) Position Lessened by Man Group plc
11:06am, Sunday, 05'th Apr 2020
Man Group plc decreased its stake in Pacific Biosciences of California (NASDAQ:PACB) by 39.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exc
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 8.3%
09:30am, Sunday, 05'th Apr 2020
Pacific Biosciences of California (NASDAQ:PACB) dropped 8.3% on Friday . The company traded as low as $2.54 and last traded at $2.65, approximately 1,468,402 shares traded hands during mid-day trading
Dublin, April 02, 2020 -- The "Global RNA Sequencing Market: Focus on Product, Technology, Workflow, End User, Application, Region, and Competitive Landscape - Analysis and.
$21.37 Million in Sales Expected for Pacific Biosciences of California (NASDAQ:PACB) This Quarter
05:56am, Wednesday, 01'st Apr 2020
Equities analysts expect Pacific Biosciences of California (NASDAQ:PACB) to report sales of $21.37 million for the current quarter, according to Zacks. Three analysts have made estimates for Pacific B
Capital International Investors Purchases Shares of 5,281,800 Pacific Biosciences of California (NASDAQ:PACB)
11:22am, Sunday, 29'th Mar 2020
Capital International Investors purchased a new stake in shares of Pacific Biosciences of California (NASDAQ:PACB) in the 4th quarter, according to the company in its most recent disclosure with the S
14,456 Shares in Pacific Biosciences of California (NASDAQ:PACB) Acquired by Blueshift Asset Management LLC
10:26am, Sunday, 29'th Mar 2020
Blueshift Asset Management LLC acquired a new position in shares of Pacific Biosciences of California (NASDAQ:PACB) during the 4th quarter, according to the company in its most recent disclosure with
The RNA sequencing industry analysis projects the market to grow at a significant CAGR of 14.21% during the forecast period, 2019-2028
08:53am, Thursday, 26'th Mar 2020
New York, March 26, 2020 -- Reportlinker.com announces the release of the report "Global RNA Sequencing Market: Focus on Product, Technology, Workflow, End User, Application,.
Global HLA Typing Market is Projected to Reach USD 1.7 Billion by 2025, at a CAGR of 5.9% - ResearchAndMarkets.com
11:40am, Wednesday, 25'th Mar 2020
The "HLA Typing Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent), Application (Cancer Research, Infectious & Non Infectious Diseases, Transfusion Therapy), End User (H
Pacific Biosciences of California (NASDAQ:PACB) Shares Acquired by Bank of Montreal Can
10:52am, Wednesday, 25'th Mar 2020
Bank of Montreal Can increased its holdings in Pacific Biosciences of California (NASDAQ:PACB) by 32.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange
